{'fraction_non_alphanumeric': 0.030805687203791468, 'fraction_numerical': 0.011848341232227487, 'mean_word_length': 5.507692307692308, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Properties of GLP‐1 agonists and their use in type 2 diabetes

There are currently four glucagon‐like peptide‐1 (GLP‐1) receptor agonists licensed for use in the treatment of type 2 diabetes in the UK: dulaglutide, exenatide, liraglutide and lixisenatide. Steve Chaplin gives an overview of their indications, mode of administration and adverse effects, and Professor Stephen Bain discusses their current place in therapy.